EA200100892A1 - Гуманизированный иммуноглобулин (варианты) и способ его получения (варианты), фармацевтическая композиция, клетка-хозяин (варианты), выделенная нуклеиновая кислота (варианты), слитый ген (варианты), способ ингибирования взаимодействия клеток (варианты), способ лечения (варианты), способ определения наличия или отсутствия b7 в образце (варианты), способ трансплантации клеток субъекту, способ модуляции иммунного ответа субъекта, способ снижения ответа антитела на антиген у млекопитающего, - Google Patents

Гуманизированный иммуноглобулин (варианты) и способ его получения (варианты), фармацевтическая композиция, клетка-хозяин (варианты), выделенная нуклеиновая кислота (варианты), слитый ген (варианты), способ ингибирования взаимодействия клеток (варианты), способ лечения (варианты), способ определения наличия или отсутствия b7 в образце (варианты), способ трансплантации клеток субъекту, способ модуляции иммунного ответа субъекта, способ снижения ответа антитела на антиген у млекопитающего,

Info

Publication number
EA200100892A1
EA200100892A1 EA200100892A EA200100892A EA200100892A1 EA 200100892 A1 EA200100892 A1 EA 200100892A1 EA 200100892 A EA200100892 A EA 200100892A EA 200100892 A EA200100892 A EA 200100892A EA 200100892 A1 EA200100892 A1 EA 200100892A1
Authority
EA
Eurasian Patent Office
Prior art keywords
variants
anthem
subject
cells
anthony
Prior art date
Application number
EA200100892A
Other languages
English (en)
Inventor
Максимилиано Васкес
Гертруда М. Вельдман
Сэмьюель Гоулдмэн
Гэри С. Грей
Беатрис Каррено
Ман Сунг Ко
Мэри Коллинс
Эндре Найт
Дэнисе О'Хара
Бонита Рап
Абби Черил Селникер
Гарвин Уорнер
Стюарт Фридрик
Original Assignee
Джинетикс Инститьют, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джинетикс Инститьют, Инк. filed Critical Джинетикс Инститьют, Инк.
Priority claimed from PCT/US2000/003303 external-priority patent/WO2000047625A2/en
Publication of EA200100892A1 publication Critical patent/EA200100892A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к гуманизированным антителам против В7-2 и В7-1, каждое из которых содержит вариабельную область нечеловеческой природы и, по меньшей мере, часть иммуноглобулина человеческой природы. Изобретение касается также способов лечения различных аутоиммунных заболеваний, отторжения трансплантата, воспалительных нарушений и инфекционных болезней путем введения гуманизированных антител против В7-2 и/или В7-1.Отчет о международном поиске был опубликован 2001.08.02.
EA200100892A 1999-02-12 2000-02-09 Гуманизированный иммуноглобулин (варианты) и способ его получения (варианты), фармацевтическая композиция, клетка-хозяин (варианты), выделенная нуклеиновая кислота (варианты), слитый ген (варианты), способ ингибирования взаимодействия клеток (варианты), способ лечения (варианты), способ определения наличия или отсутствия b7 в образце (варианты), способ трансплантации клеток субъекту, способ модуляции иммунного ответа субъекта, способ снижения ответа антитела на антиген у млекопитающего, EA200100892A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/249,011 US6972125B2 (en) 1999-02-12 1999-02-12 Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
US09/339,596 US6913747B1 (en) 1999-02-12 1999-06-24 Humanized immunoglobulin reactive with B7 therewith
PCT/US2000/003303 WO2000047625A2 (en) 1999-02-12 2000-02-09 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith

Publications (1)

Publication Number Publication Date
EA200100892A1 true EA200100892A1 (ru) 2002-02-28

Family

ID=22941666

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100892A EA200100892A1 (ru) 1999-02-12 2000-02-09 Гуманизированный иммуноглобулин (варианты) и способ его получения (варианты), фармацевтическая композиция, клетка-хозяин (варианты), выделенная нуклеиновая кислота (варианты), слитый ген (варианты), способ ингибирования взаимодействия клеток (варианты), способ лечения (варианты), способ определения наличия или отсутствия b7 в образце (варианты), способ трансплантации клеток субъекту, способ модуляции иммунного ответа субъекта, способ снижения ответа антитела на антиген у млекопитающего,

Country Status (6)

Country Link
US (5) US6972125B2 (ru)
KR (1) KR20020002389A (ru)
AR (1) AR022575A1 (ru)
EA (1) EA200100892A1 (ru)
HK (1) HK1042708A1 (ru)
ZA (1) ZA200106982B (ru)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
CN1360596A (zh) * 1999-02-12 2002-07-24 遗传研究所有限公司 与b7分子发生反应的人源化免疫球蛋白及应用该免疫球蛋白的治疗方法
WO2001068133A1 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
WO2001068134A2 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Therapies that improve graft survival, using antibodies against a b7 antigen
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
WO2004040969A1 (ja) * 2002-11-07 2004-05-21 Kumamoto Technology & Industry Foundation Ｇａｎｐ導入トランスジェニック哺乳動物及びその利用
AU2005322874A1 (en) * 2004-12-31 2006-07-13 Genentech, Inc. Detecting human antibodies in non-human serum
EP3623473A1 (en) * 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2981431C (en) 2005-06-08 2021-04-13 Dana-Farber Cancer Institute Inc. Use of compounds that reduce activity or expression of programmed cell death-1 to treat lymphoma
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
JP5624276B2 (ja) * 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
DK2021463T3 (en) * 2006-05-19 2017-01-16 Alder Biopharmaceuticals Inc Culture method to obtain a cloned population of antigen-specific B cells
EP2133365B1 (en) * 2006-12-27 2017-05-17 Emory University Compositions and methods for the treatment of infections and tumors
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
CA2688146C (en) * 2007-05-21 2018-03-06 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
KR20080103637A (ko) * 2007-05-25 2008-11-28 주식회사 알앤엘바이오 지방유래 줄기세포를 함유하는 사지말단부 허혈성 질환의세포치료용 조성물
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
ES2566957T3 (es) * 2007-09-26 2016-04-18 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
EP2236604B1 (en) 2007-12-05 2016-07-06 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody and use thereof
US8921523B2 (en) * 2007-12-11 2014-12-30 Glaxo Group Limited Humanized anti-beta-amyloid antibodies
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
ES2657220T3 (es) 2008-10-02 2018-03-02 Aptevo Research And Development Llc Proteínas de unión multi-diana antagonistas de CD86
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
HUE028582T2 (en) * 2008-11-28 2016-12-28 Univ Emory Method for determining the efficacy of PD-1 antagonists
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
MX2011012136A (es) 2009-05-15 2012-04-10 Chugai Pharmaceutical Co Ltd Anticuerpo anti-axl.
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
EP2504031A4 (en) 2009-11-24 2013-06-26 Alderbio Holdings Llc ANTI-IL-6 ANTIBODIES AND THEIR USE
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
CN101704892B (zh) * 2009-12-09 2014-02-12 中国人民解放军军事医学科学院生物工程研究所 一种抗uPAR人源化抗体及其编码基因与应用
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
MX355060B (es) 2010-11-17 2018-04-03 Chugai Pharmaceutical Co Ltd Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
CA2818814A1 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
US20140093496A1 (en) 2011-02-25 2014-04-03 Chugai Seiyaku Kabushiki Kaisha Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
DK3050896T3 (da) 2013-09-27 2021-07-19 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af en polypeptid-heteromultimer
TWI734975B (zh) * 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN113045650A (zh) 2014-12-19 2021-06-29 中外制药株式会社 抗-c5抗体及使用方法
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
KR101892883B1 (ko) 2015-02-27 2018-10-05 추가이 세이야쿠 가부시키가이샤 Il-6 관련 질환 치료용 조성물
KR102129107B1 (ko) * 2015-03-06 2020-07-02 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 항-lilrb 항체 및 암의 검출 및 치료를 위한 이의 용도
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
JP7219005B2 (ja) 2015-12-28 2023-02-07 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
TW202214700A (zh) 2016-03-14 2022-04-16 日商中外製藥股份有限公司 用於癌之治療的細胞傷害誘導治療劑
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP0623679B1 (en) * 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DK0528767T3 (da) 1991-08-21 2000-04-17 Novartis Ag antistofderivater
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5747034A (en) 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
CA2115811A1 (en) * 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
JPH09500788A (ja) 1993-07-26 1997-01-28 ダナ・ファーバー・キャンサー・インスティテュート・インコーポレイテッド Ｂ７−２：ｃｔｌａ４／ｃｄ２８カウンターレセプター
US6084067A (en) * 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
US6130316A (en) * 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
US6218510B1 (en) * 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
US5679340A (en) * 1994-03-31 1997-10-21 Diacrin, Inc. Cells with multiple altered epitopes on a surface antigen for use in transplantation
CA2191733A1 (en) 1994-06-07 1995-12-21 Daniel A. Vallera Methods for inhibiting antigen specific t cell responses
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
WO1996014865A1 (en) 1994-11-10 1996-05-23 Repligen Corporation Methods for inhibiting graft versus host disease in bone marrow transplantation
US5919449A (en) * 1995-05-30 1999-07-06 Diacrin, Inc. Porcine cardiomyocytes and their use in treatment of insufficient cardiac function
EP0831917A2 (en) * 1995-06-07 1998-04-01 Innogenetics N.V. Immunotoxins specific for cd80 and cd86 expressing cells
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
ID21676A (id) 1996-11-08 1999-07-08 Idec Pharma Corp Identifikasi interaksi-interaksi ikatan yang khas antara antibodi-antibodi dan antigen-antigen pembantu rangsangan b7.1 dan b7.2 manusia tertentu
AU746825B2 (en) * 1998-02-04 2002-05-02 Brigham And Women's Hospital Costimulatory blockade and mixed chimerism in allotransplantation
US6587142B1 (en) 1998-09-09 2003-07-01 Pictos Technologies, Inc. Low-noise active-pixel sensor for imaging arrays with high speed row reset
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith

Also Published As

Publication number Publication date
KR20020002389A (ko) 2002-01-09
US6984383B1 (en) 2006-01-10
US6972125B2 (en) 2005-12-06
US7666421B2 (en) 2010-02-23
US6913747B1 (en) 2005-07-05
HK1042708A1 (zh) 2002-08-23
ZA200106982B (en) 2002-12-11
US20020176855A1 (en) 2002-11-28
AR022575A1 (es) 2002-09-04
US20060251645A1 (en) 2006-11-09
US6827934B1 (en) 2004-12-07

Similar Documents

Publication Publication Date Title
EA200100892A1 (ru) Гуманизированный иммуноглобулин (варианты) и способ его получения (варианты), фармацевтическая композиция, клетка-хозяин (варианты), выделенная нуклеиновая кислота (варианты), слитый ген (варианты), способ ингибирования взаимодействия клеток (варианты), способ лечения (варианты), способ определения наличия или отсутствия b7 в образце (варианты), способ трансплантации клеток субъекту, способ модуляции иммунного ответа субъекта, способ снижения ответа антитела на антиген у млекопитающего,
Noelle et al. Cognate interactions between helper T cells and B cells. V. Reconstitution of T helper cell function using purified plasma membranes from activated Th1 and Th2 T helper cells and lymphokines.
CN1260249C (zh) 用离子交换层析纯化蛋白质
Engels et al. Memory control by the B cell antigen receptor
AU7729594A (en) Methods and composition for the modulation of host immune response to allergens
RU2000111483A (ru) Природные гуманизированные антитела
Shores et al. Multifactorial design of a supramolecular peptide anti-IL-17 vaccine toward the treatment of psoriasis
WO2008045140A1 (en) Culture method for obtaining a clonal population of antigen-specific b cells
DK0613944T3 (da) Fremgangsmåder til regulering af immunresponset under anvendelse af CTLA4-bindende molekyler og IL4-bindende molekyler
RU2006143686A (ru) Антитела
CN104678106A (zh) 单克隆抗体stro-4
Cheng et al. Selective depletion of plasma cells in vivo based on the specificity of their secreted antibodies
Samuels et al. Human B cell tolerance and its failure in rheumatoid arthritis
Hansson et al. Fc-mediated binding of IgG to vimentin-type intermediate filaments in vascular endothelial cells.
ES2112869T3 (es) Anticuerpos monoclonales contra celulas de islotes del pancreas humano.
CN103910796B (zh) 一种全人源抗狂犬病毒的中和抗体
Becza et al. Assessing the affinity spectrum of the antigen-specific B cell repertoire via ImmunoSpot®
Fink et al. B cell activation state-governed formation of germinal centers following viral infection
Liedgens et al. Highly efficient purification of the labile plant enzyme 5-aminolevulinate dehydratase (EC 4.2. 1.24) by means of monoclonal antibodies
Jack et al. Immunoaffinity chromatography of clinical products
Campbell Production and purification of antibodies
Dehghanpisheh et al. Retrovirally induced mouse anti‐TCR monoclonals can synergize the in vitro proliferative T cell response to bacterial superantigens
Van Den Eertwegh et al. In vivo TB cell interactions and cytokine-production in the spleen
Michaelsen et al. A mutant human IgG molecule with only one C1q binding site can activate complement and induce lysis of target cells
Lindeborg et al. Biological activity of pig islet‐cell reactive IgG antibodies in xenotransplanted diabetic patients